期刊的影响因子--文章列表

期刊文章列表
Hui Liu¹，Weimin Qiu¹，Tianyu Sun¹，Lei Wang¹，Chenxi Du¹，Yanyu Hu²，Wenyuan Liu^1,3，Feng Feng^4,2，Yao Chen⁵，Haopeng Sun^1,4（School of Pharmacy，China Pharmaceutical University；Department of Natural Medicinal Chemistry，China Pharmaceutical University；Department of Pharmaceutical Analysis，Key Laboratory of Drug Quality Control and Pharmacovigilance，China Pharmaceutical University；Jiangsu Drug Development Engineering Research Center for Central Degenerative Disease，Jiangsu Food and Pharmaceuticals Science College；School of Pharmacy，Nanjing University of Chinese Medicine）.Therapeutic strategies of glioblastoma（GBM）：The current advances in the molecular targets and bioactive small molecule compounds[J].Acta Pharmaceutica Sinica B,2022,第4期 Yang He^1,2,3,4，Yuefei Fang^1,5，Meng Zhang^1,6，Yuge Zhao¹，Bin Tu^1,2，Mingjie Shi¹，Bahtiyor Muhitdinov^1,7，Akmal Asrorov^1,7，Qin Xu⁵，Yongzhuo Huang^1,2,3,8（State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；Zhongshan Institute for Drug Discovery，Chinese Academy of Sciences；Department of Pharmacy，the First Affiliated Hospital of Zhengzhou University；Artemisinin Research Center，Guangzhou University of Chinese Medicine；Women's Hospital，School of Medicine，Zhejiang University；Institute of Bioorganic Chemistry，Uzbekistan Academy of Sciences；National Medical Products Administration，Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients）.Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona[J].Acta Pharmaceutica Sinica B,2022,第4期 Shuai Guo，Kening Li，Yanwen Chen，Bin Li（State Key Laboratory of Natural Medicines and School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Unraveling the drug distribution in brain enabled by MALDI MS imaging with laser-assisted chemical transfer[J].Acta Pharmaceutica Sinica B,2022,第4期 Yongrong Yao，Huachao Chen，Ninghua Tan（State Key Laboratory of Natural Medicines，School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiqiang Deng¹，Yu Dong¹，Xiaoting Zhou^2,3，Jia-Hong Lu¹，Zhenyu Yue²（State Key Laboratory of Quality Research in Chinese Medicine，Institute of Chinese Medical Sciences，University of Macau；Department of Neurology，the Friedman Brain Institute，Icahn School of Medicine at Mount Sinai；Department of Geriatrics，Xiangya Hospital，Central South University）.Pharmacological modulation of autophagy for Alzheimer’s disease therapy：Opportunities and obstacles[J].Acta Pharmaceutica Sinica B,2022,第4期 Jie Zhou¹，Wei Xu¹，Zezhong Liu¹，Chao Wang²，Shuai Xia¹，Qiaoshuai Lan¹，Yanxing Cai¹，Shan Su¹，Jing Pu¹，Lixiao Xing¹，Youhua Xie¹，Lu Lu¹，Shibo Jiang¹，Qian Wang¹（Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)，School of Basic Medical Sciences and BSL-3 Facility，Shanghai Institute of Infectious Diseases and Biosecurity，Fudan University；State Key Laboratory of Toxicology and Medical Countermeasures，Beijing Institute of Pharmacology and Toxicology）.A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases[J].Acta Pharmaceutica Sinica B,2022,第4期 Xuejing Shao¹，Yingqian Chen¹，Wei Wang¹，Wenxin Du¹，Xingya Zhang¹，Minyi Cai¹，Shaowei Bing¹，Ji Cao^1,2,3，Xiaojun Xu⁴，Bo Yang^1,3，Qiaojun He^1,2,3，Meidan Ying^1,4,2（Institute of Pharmacology and Toxicology，Zhejiang Province Key Laboratory of Anti-Cancer Drug Research，College of Pharmaceutical Sciences，Zhejiang University；Cancer Center，Zhejiang University；Innovation Institute for Artificial Intelligence in Medicine，Zhejiang University；Children's Hospital，Zhejiang University School of Medicine，National Clinical Research Center for Child Health）.Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhidi Pan¹，Jie Chen¹，Xiaodong Xiao^2,3，Yueqing Xie²，Hua Jiang^2,3，Baohong Zhang¹，Huili Lu¹，Yunsheng Yuan¹，Lei Han³，Yuexian Zhou¹，Huifang Zong¹，Lei Wang¹，Rui Sun¹，Jianwei Zhu^1,2,3（Engineering Research Center of Cell&Therapeutic Antibody，MOE，School of Pharmacy，Shanghai Jiao Tong University；Jecho Laboratories，Inc.；Jecho Biopharmaceuticals Co.，Ltd.）.Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement[J].Acta Pharmaceutica Sinica B,2022,第4期 Minsong Guo¹，Fengdan Zhu¹，Wenqiao Qiu^1,2，Gan Qiao¹，Betty Yuen-Kwan Law³，Lu Yu¹，Jianming Wu¹，Yong Tang^1,3，Chonglin Yu¹，Dalian Qin¹，Xiaogang Zhou¹，Anguo Wu¹（Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation，Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica，School of Pharmacy，Education Ministry Key Laboratory of Medical Electrophysiology，Southwest Medical University；Department of Neurosurgery Sichuan Provincial People's Hospital，University of Electronic Science and Technology of China；State Key Laboratory of Quality Research in Chinese Medicine，Macau University of Science and Technology）.High-throughput screening for amyloid-β binding natural small-molecules based on the combinational use of biolayer interferometry and UHPLC-DAD-Q/TOF-MS/MS[J].Acta Pharmaceutica Sinica B,2022,第4期 Sameera Senaweera¹，Tiffany C.Edwards¹，Jayakanth Kankanala¹，Yan Wang^1,2，Rajkumar Lalji Sahani¹，Jiashu Xie¹，Robert J.Geraghty¹，Zhengqiang Wang¹（Center for Drug Design，College of Pharmacy，University of Minnesota；Translational Medicine R&D Center，Shenzhen Institutes of Advanced Technology，Chinese Academy of Sciences）.Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus（HCMV）[J].Acta Pharmaceutica Sinica B,2022,第4期 Chuanbin Yang^1,2，Chengfu Su^1,3,4，Ashok Iyaswamy^1,3，Senthil Kumar Krishnamoorthi¹，Zhou Zhu^1,3，Sichang Yang¹，Benjamin Chunkit Tong^1,3，Jia Liu^1,3，Sravan G.Sreenivasmurthy^1,3，Xinjie Guan¹，Yuxuan Kan¹，Aston Jiaxi Wu¹，Alexis Shiying Huang¹，Jieqiong Tan⁵，Kingho Cheung^1,3，Juxian Song^1,6，Min Li^1,3（Mr.&Mrs.Ko Chi-Ming Centre for Parkinson's Disease Research，School of Chinese Medicine，Hong Kong Baptist University；Department of Geriatrics，Shenzhen People's Hospital(the Second Clinical Medical College，Jinan University，the First Affiliated Hospital，Southern University of Science and Technology)；Institute for Research and Continuing Education，Hong Kong Baptist University；College of Pharmacy，Henan University of Chinese Medicine；Center for Medical Genetics and Hunan Key Laboratory of Animal Model for Human Diseases，School of Life Sciences，Central South University；Medical College of Acupuncture-Moxibustion and Rehabilitation，Guangzhou University of Chinese Medicine）.Celastrol enhances transcription factor EB（TFEB）-mediated autophagy and mitigates Tau pathology：Implications for Alzheimer’s disease therapy[J].Acta Pharmaceutica Sinica B,2022,第4期 Jun Wang，Yanmei Hu，Madeleine Zheng（Department of Pharmacology and Toxicology，College of Pharmacy，the University of Arizona）.Enterovirus A71 antivirals：Past, present, and future[J].Acta Pharmaceutica Sinica B,2022,第4期 Mengqi Xu¹，Cong Mao²，Haoting Chen²，Lu Liu³，Yabin Wang¹，Abid Hussain³，Sulei Li¹，Xu Zhang⁴，Ruslan G.Tuguntaev²，Xing-Jie Liang³，Weisheng Guo²，Feng Cao¹（Department of Cardiology，National Clinical Research Center for Geriatric Diseases&Second Medical Center of Chinese PLA General Hospital；Department of Minimally Invasive Interventional Radiology，Key Laboratory of Molecular Target&Clinical Pharmacology，School of Pharmaceutical Sciences&the Second Affiliated Hospital，Guangzhou Medical University；Laboratory of Controllable Nanopharmaceuticals，Chinese Academy of Sciences(CAS)Center for Excellence in Nanoscience and CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety，National Center for Nanoscience and Technology；Department of Urology，Chinese PLA General Hospital）.Osteopontin targeted theranostic nanoprobes for laser-induced synergistic regression of vulnerable atherosclerotic plaques[J].Acta Pharmaceutica Sinica B,2022,第4期 Saba R.Aliyari¹，Amir Ali Ghaffari¹，Olivier Pernet^1,2，Kislay Parvatiyar¹，Yao Wang¹，Hoda Gerami¹，Ann-Jay Tong¹，Laurent Vergnes³，Armin Takallou¹，Adel Zhang¹，Xiaochao Wei⁴，Linda D.Chilin⁵，Yuntao Wu⁵，Clay F.Semenkovich^4,6，Karen Reue³，Stephen T.Smale¹，Benhur Lee¹，Genhong Cheng¹（Department of Microbiology，Immunology and Molecular Genetics，University of California；En Viro International Laboratories；Department of Human Genetics，David Geffen School of Medicine，University of California；Division of Endocrinology，Metabolism and Lipid Research，Washington University School of Medicine；Center for Infectious Disease Research，School of Systems Biology，George Mason University Manassas；Diabetic Cardiovascular Disease Center，Washington，University School of Medicine）.Suppressing fatty acid synthase by type Ⅰ interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2[J].Acta Pharmaceutica Sinica B,2022,第4期 Boyi Niu¹，Yixian Zhou¹，Kaixin Liao¹，Ting Wen¹，Sixian Lao¹，Guilan Quan²，Xin Pan¹，Chuanbin Wu^1,2（School of Pharmaceutical Sciences，Sun Yat-sen University；College of Pharmacy，Jinan University）.“Pincer movement”：Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles[J].Acta Pharmaceutica Sinica B,2022,第4期 Chunlong Ma，Haozhou Tan，Juliana Choza，Yuyin Wang，Jun Wang（Department of Pharmacology and Toxicology，College of Pharmacy，the University of Arizona）.Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiwei Zhang^1,2，Suling Ding¹，Zhe Wang³，Xiaowei Zhu¹，Zheliang Zhou¹，Weiwei Zhang¹，Xiangdong Yang^1,3,4,5，Junbo Ge^1,3,4,5（Institutes of Biomedical Sciences and Shanghai Institute of Cardiovascular Diseases，Zhongshan Hospital，Fudan University；Reproductive Medicine Centre，Zhongshan Hospital，Fudan University；Department of Cardiology，Zhongshan Hospital，Fudan University；NHC Key Laboratory of Viral Heart Diseases，Fudan University；Key Laboratory of Viral Heart Diseases，Chinese Academy of Medical Sciences）.Prmt1 upregulated by Hdc deficiency aggravates acute myocardial infarction via NETosis[J].Acta Pharmaceutica Sinica B,2022,第4期 Hsiang-i Tsai^1,2，Yanping Wu¹，Rui Huang³，Dandan Su¹，Yingyi Wu¹，Xiaoyan Liu¹，Linglu Wang¹，Zhanxue Xu¹，Yuxin Pang⁴，Chong Sun⁵，Chao He¹，Fan Shu¹，Haitao Zhu²，Dongqing Wang²，Fang Cheng¹，Laiqiang Huang⁶，Hongbo Chen¹（School of Pharmaceutical Sciences(Shenzhen)，Sun Yat-sen University；Department of Medical Imaging，the Affiliated Hospital of Jiangsu University；Department of Hematology，Zhujiang Hospital，Southern Medical University；School of Traditional Medicine Materials Resource，Guangdong Pharmaceutical University；Immune Regulation in Cancer，German Cancer Research Center；The Shenzhen Key Lab of Gene and Antibody Therapy，Center for Biotechnology&Biomedicine，Division of Life and Health Sciences，Graduate School at Shenzhen，Tsinghua University）.PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia[J].Acta Pharmaceutica Sinica B,2022,第4期 Yunlong Shan¹，Qi Ni¹，Qixiang Zhang¹，Mengying Zhang¹，Bin Wei²，Lingge Cheng¹，Chongjin Zhong¹，Xinyu Wang¹，Qingqing Wang¹，Jiali Liu¹，Jingwei Zhang¹，Jingjing Wu²，Guangji Wang¹，Fang Zhou¹（Key Laboratory of Drug Metabolism and Pharmacokinetics，State Key Laboratory of Natural Medicines，China Pharmaceutical University；Department of Hematology and Oncology，the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University）.Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment[J].Acta Pharmaceutica Sinica B,2022,第4期 Yuyun Tang¹，Jinchao Gao¹，Tao Wang²，Qian Zhang¹，Antian Wang¹，Meng Huang¹，Renhe Yu¹，Hongzhuan Chen^1,3，Xiaoling Gao¹（Department of Pharmacology and Chemical Biology，Shanghai Universities Collaborative Innovation Center for Translational Medicine，Shanghai Jiao Tong University School of Medicine；Department of Geriatric Psychiatry，Shanghai Mental Health Center，Shanghai Jiao Tong University School of Medicine，Alzheimer's Disease and Related Disorder Center，Shanghai Jiao Tong University；Institute of Interdisciplinary Integrative Biomedical Research，Shuguang Hospital，Shanghai University of Traditional Chinese Medicine）.The effect of drug loading and multiple administration on the protein corona formation and brain delivery property of PEG-PLA nanoparticles[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhong Li^1,2，Jimin Xu³，Yuekun Lang²，Xiangmeng Wu¹，Saiyang Hu²，Subodh Kumar Samrat^1,2，Anil M.Tharappel^1,2，Lili Kuo²，David Butler⁴，Yongcheng Song⁵，Qing-Yu Zhang¹，Jia Zhou³，Hongmin Li^1,2（Department of Pharmacology and Toxicology，College of Pharmacy；Wadsworth Center，New York State Department of Health；Chemical Biology Program，Department of Pharmacology and Toxicology，University of Texas Medical Branch；The Neural Stem Cell Institute；Department of Pharmacology and Chemical Biology，Baylor College of Medicine）.In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus[J].Acta Pharmaceutica Sinica B,2022,第4期 Songli Wang^1,2，Ruifeng Wang¹，Nana Meng¹，Linwei Lu³，Jun Wang¹，Jianfen Zhou¹，Jiasheng Lu¹，Qianzhu Xu¹，Cao Xie¹，Changyou Zhan^1,2，Yao Li⁴，Yang Yu⁴，Weiyue Lu^1,5,6，Min Liu¹（Department of Pharmaceutics，School of Pharmacy，Key Laboratory of Smart Drug Delivery(Ministry of Education and PLA)，Fudan University；Department of Pharmacology，School of Basic Medical Sciences，Fudan University；The Department of Integrative Medicine，Huashan Hospital，Fudan University and the Institutes of Integrative Medicine of Fudan University；The National Facility for Protein Science in Shanghai(NFPS)；State Key Laboratory of Medical Neurobiology and the Collaborative Innovation Center for Brain Science and Department of Pharmacology，School of Basic Medical Sciences，Fudan University；Minhang Branch，Zhongshan Hospital and Institute of Fudan-Minhang Academic Health System，Minhang Hospital，Fudan University）.Engineered platelets-based drug delivery platform for targeted thrombolysis[J].Acta Pharmaceutica Sinica B,2022,第4期 Hong Wang¹，Qianqian Wang¹，Guodi Cai¹，Zhijian Duan²，Zoann Nugent³，Jie Huang⁴，Jianwei Zheng¹，Alexander D.Borowsky⁵，Jian Jian Li⁶，Peiqing Liu^1,7，Hsing-Jien Kung^2,8，Leigh Murphy³，Hong-Wu Chen^2,8，Junjian Wang^1,7（School of Pharmaceutical Sciences，Sun Yat-sen University；Department of Biochemistry and Molecular Medicine，University of California；Research Institute in Oncology and Hematology，University of Manitoba and Cancer Care Manitoba；Guangdong Lung Cancer Institute，Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer，Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences；Department of Pathology and Laboratory Medicine，University of California；Department of Radiation Oncology，University of California；National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation，Guangdong Provincial Key Laboratory of New Drug Design and Evaluation，Sun Yat-sen University；UC Davis Comprehensive Cancer Center，School of Medicine，University of California）.Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop via NRF2 in cancer therapeutic resistance[J].Acta Pharmaceutica Sinica B,2022,第4期 Qi Wang^1,2，Bixi Tang^3,2,4，Dandan Sun⁵，Ying Dong^3,2，Yinchun Ji⁶，Huanyu Shi^1,2，Liwei Zhou^1,7，Yueyue Yang^1,2，Menglan Luo^1,8，Qian Tan³，Lin Chen¹，Yue Dong⁹，Cong Li³，Rongrong Xie³，Yi Zang^3,2,10，Jingkang Shen¹，Bing Xiong^1,2，Jia Li^3,2,5,10，Danqi Chen¹（Department of Medicinal Chemistry，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；Department of Pharmacology，School of Pharmacy，Fudan University；School of Chinese Materia Medica，Nanjing University of Chinese Medicine；Division of Anti-tumor Pharmacology，State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；Center for Supramolecular Chemistry and Catalysis and Department of Chemistry，College of Sciences，Shanghai University；Department of Chemistry，College of Sciences，Shanghai University；Department of Pulmonary and Critical Care Medicine，Shanghai Fifth People’s Hospital，Fudan University；School of Pharmaceutical Science and Technology，Hangzhou Institute for Advanced Study，UCAS）.Discovery of 4-cyclopropyl-3-（2-（（1-cyclopropyl-1H-pyrazol-4-yl） amino） quinazolin-6-yl）-N-（3-（trifiuoromethyl） phenyl） benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis[J].Acta Pharmaceutica Sinica B,2022,第4期 Mélanie Robert^1,2,3，Bastien Laperrousaz¹，Diana Piedrahita¹，Emilie-Fleur Gautier^3,4，Travis Nemkov^5,6，Florian Dupuy^4,7，Elie Nader^2,3，Virginie Salnot⁴，Patrick Mayeux^3,4，Angelo D’Alessandro^5,6，Catherine Lavazec^4,7，Philippe Joly^2,3,8，Alexander Scheer¹，Philippe Connes^2,3，Agnès Cibiel¹（Erytech Pharma；Laboratoire interuniversitaire de Biologie de la Motricité(LIBM)EA7424，Team?Vascular Biology and Red Blood Cell?，Université Claude Bernard Lyon 1，Université de Lyon；Labex GR-Ex；3P5 proteom’IC facility，Université de Paris，Institut Cochin，INSERM，CNRS；University of Colorado，Anschutz Medical Campus；Omix Technologies，Inc.；Inserm U1016，CNRS 8104，Université de Paris，Institut Cochin；Laboratoire de Biochimie et de Biologie Moléculaire，UF de biochimie des pathologies érythrocytaires，Centre de Biologie et de Pathologie Est，Hospices Civils de Lyon）.Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process[J].Acta Pharmaceutica Sinica B,2022,第4期 Rong Xiang¹，Zhengsen Yu¹，Yang Wang¹，Lili Wang²，Shanshan Huo¹，Yanbai Li¹，Ruiying Liang¹，Qinghong Hao¹，Tianlei Ying³，Yaning Gao⁴，Fei Yu¹，Shibo Jiang³（College of Life Sciences，Hebei Agricultural University；Research Center of Chinese Jujube，Hebei Agricultural University；Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)，School of Basic Medical Sciences，Shanghai Institute of Infectious Diseases and Biosecurity，Fudan University；Beijing Pharma and Biotech Center）.Recent advances in developing small-molecule inhibitors against SARS-CoV-2[J].Acta Pharmaceutica Sinica B,2022,第4期 Lei Feng^1,2，Xiangge Tian²，Dahong Yao³，Zhenlong Yu²，Xiaokui Huo^1,2，Zhenhao Tian⁴，Jing Ning²，Jingnan Cui⁴，Tony D.James^5,6，Xiaochi Ma^1,2（Second Affiliated Hospital，Dalian Medical University；College of Pharmacy，the National&Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease，Dalian Medical University；School of Pharmaceutical Sciences，Shenzhen Technology University；State Key Laboratory of Fine Chemicals，Dalian University of Technology；Department of Chemistry，University of Bath；School of Chemistry and Chemical Engineering，Henan Normal University）.A practical strategy to develop isoform-selective near-infrared fiuorescent probes for human cytochrome P450 enzymes[J].Acta Pharmaceutica Sinica B,2022,第4期 He Xueqin，Wang Xiaorong，Yang Lianyi，Yang Zhihang，Yu Wenqi，Wang Yazhen，Liu Rui，Chen Meiwan，Gao Huile（West China School of Pharmacy，Sichuan University，Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province，Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology；Institute of Chinese Medical Sciences，University of Macau，State Key Laboratory of Quality Research in Chinese Medicine）.Intelligent lesion blood-brain barrier targeting nano-missiles for Alzheimers disease treatment by anti-neuroinflammation and neuroprotection[J].Acta Pharmaceutica Sinica B,2022,第4期 Guo Minsong Zhu Fengdan Qiu Wenqiao Qiao Gan Law Betty Yuenkwan Yu Lu Wu Jianming Tang Yong Yu Chonglin Qin Dalian Zhou Xiaogang Wu Anguo（School of Pharmacy， Southwest Medical University， Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation；Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica；Education Ministry Key Laboratory of Medical Electrophysiology， Luzhou， 646000;Department of Neurosurgery Sichuan Provincial Peoples Hospital， University of Electronic Science and Technology of China， Chengdu， 610000;Macau University of Science and Technology， State Key Laboratory of Quality Research in Chinese Medicine， Macau， Taipa， 999078;Macau University of Science and Technology， State Key， Macau， Taipa， 999078）.High-throughput screening for amyloid-β binding natural small-molecules based on the combinational use of biolayer interferometry and UHPLCLDAD-Q/TOF-MS/MS[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiwei Xiao^1,2，Huiyi Wei¹，Yi Xu³，Ahmed Haider²，Junjie Wei¹，Shiyu Yuan¹，Jian Rong²，Chunyu Zhao²，Guocong Li¹，Weibin Zhang⁴，Huangcan Chen⁴，Yuefeng Li⁵，Lingling Zhang¹，Jiyun Sun^1,2，Shaojuan Zhang¹，Hai-Bin Luo⁶，Sen Yan⁷，Qijun Cai¹，Lu Hou¹，Chao Che⁴，Steven H.Liang²，Lu Wang¹（Center of Cyclotron and PET Radiopharmaceuticals，Department of Nuclear Medicine and PET/CT-MRI Center，the First Affiliated Hospital of Jinan University；Division of Nuclear Medicine and Molecular Imaging，Massachusetts General Hospital&Department of Radiology，Harvard Medical School；Department of Cardiology，the First Affiliated Hospital of Jinan University；State Key Laboratory of Chemical Oncogenomics，Key Laboratory of Chemical Genomics，Peking University Shenzhen Graduate School；Guangdong Landau Biotechnology Co.Ltd.；Key Laboratory of Tropical Biological Resources of Ministry of Education，School of Pharmaceutical Sciences，Hainan University；Guangdong-Hongkong-Macau Institute of CNS Regeneration，Ministry of Education CNS Regeneration Collaborative Joint Laboratory，Jinan University）.Discovery of a highly specific ¹⁸F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofiuorination[J].Acta Pharmaceutica Sinica B,2022,第4期首页上一页 5 6 7 8 9 下一页尾页共有11页，转到页

期刊文章列表